Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on June 12, 2019, regarding events occurring on June 11, 2019. The report details the results of the Company's 2019 Annual Meeting of Stockholders held in Deer Park, Illinois. The Company is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the completion of the Annual Meeting where stockholders voted on director elections and auditor ratification.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies. The document strictly reports the voting outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Director Election: Paul V. Maier was elected as a director for a three-year term with 9,366,965 votes "For" and 24,006 votes "Against."
- Auditor Ratification: Stockholders ratified the appointment of KMJ Corbin & Company LLP as the independent registered public accounting firm for the year ending December 31, 2019, with 10,736,108 votes "For" and 23,728 votes "Against."
- Voting Participation: There were 1,368,928 broker non-votes recorded for the director election proposal.
- Emerging Growth Status: The Company has elected not to use the extended transition period for complying with new or revised financial accounting standards.